Journal Article Summary
The article investigates the treatment patterns, healthcare resource utilization, and costs associated with two medications—atomoxetine (ATX) and long-acting methylphenidate (LA-MPH)—for children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) in Germany. ADHD is a prevalent neurobehavioral disorder that significantly impacts the lives of affected individuals and their families, making effective treatment crucial. Understanding the differences in treatment approaches and their economic implications can help inform better management strategies for ADHD.
The study analyzed data from a large electronic medical records database, focusing on children and adolescents aged 6 to 17 who began treatment with either ATX or LA-MPH between 2006 and 2010. Researchers matched patients receiving each medication to ensure comparability and evaluated treatment persistence, switching rates, and healthcare costs over a 12-month period. The findings revealed that patients on ATX had longer persistence with their medication but also higher rates of switching to other treatments compared to those on LA-MPH. Additionally, the ATX group required more prescriptions and outpatient visits, leading to significantly higher healthcare costs.
Despite its strengths, the study has limitations, including potential biases from unobserved variables and reliance on administrative data, which may not capture the full clinical picture. Patients and caregivers should discuss these findings with healthcare professionals to understand how treatment choices might affect both health outcomes and costs. It’s important to consider individual circumstances and preferences when selecting ADHD treatments, as well as the potential need for additional support services beyond medication.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Greven Peter, Sikirica Vanja, Chen Yaozhu J., Curtice Tammy G., Makin Charles. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany. The European Journal of Health Economics 2016. DOI: 10.1007/s10198-016-0836-8. PMID: 27817164. PMCID: PMC5533820.
Featured Pill Pals Product
Atomoxetine 60 mg Capsules --- Generic for Strattera --- Glenmark
Atomoxetine 60 mg Capsules — Generic for Strattera — Glenmark is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
